Assessment of Awareness and Experience of Using off-label Drugs by Doctors of Clinical Specialties

Aim      To evaluate the frequency of off-label prescription of medicines in practice of clinical specialists and the awareness of respondents of the procedure of justified off-label prescription.

Material and methods  The sample included 542 clinical specialists who worked in definite medical organizations in 26 entities of the Russian Federation. The respondents were proposed to fill in remotely an anonymous questionnaire to evaluate the experience of prescribing medicines off-label to adult patients.

Results Prescribing medicines not in consistence with the officially approved instruction for medical use (off-label or “outside instruction”) is a relevant issue of global medical care since convincing scientific evidence for safety of such use is scarce. Analysis of information about off-label prescription is one of current tasks of national medical research centers according to the Federal Project “Development of a network of national medical research centers and implementation of innovative medical technologies”. According to the responses about the frequency of off-label prescriptions 67.5 % of respondents reported of no experience of off-label prescription, 27.7 % said “rarely” or “sometimes”, and 4.8 % said “frequently” and “very frequently”. Specialties of physicians who have more often used medicines off-label (50% and more) included obstetrics and gynecology, pediatrics, rheumatology, hematology, and pulmonology. Cardiologists, neurologists and clinical pharmacologists use medicines off-label relatively rarely (19.6%, 28.6 %, and 22.2 %, respectively). 40 % of medicines used off-label were those designed for the treatment of coronavirus infection SARS-CoV-2. The medicines most frequently used off-label included metformin, rituximab, and thioctic acid. 65 % of respondents assessed their knowledge of off-label prescription as insufficient. In addition, 75 % of respondents consider it useful to receive additional information about risks and benefits of off-label prescription in clinical practice.

Conclusion      The survey revealed the need of physicians for information about risks of the off-label use of medicines in clinical practice.

1. U.S-Food and Drug Administration. Understanding Unapproved Use of Approved Drugs ‘Off Label’. 2019. [Internet] 2019. Available at: https://www.fda.gov/patients/learn-about-expanded-access-andother-treatment-options/understanding-unapproved-use-approveddrugs-label

2. Tsygankova O.V., Batluk T.I., Latyntseva L.D., Platonov D.Yu., Akhmedzhanov N.M. Legal and Medical Aspects of Off-Label Medication Use. Point of View. Rational Pharmacotherapy in Cardiology. 2019;15(1):130–4. DOI: 10.20996/1819-6446-2019-15-1-130-134

3. Aronson JK, Ferner RE. Unlicensed and off‐label uses of medicines: definitions and clarification of terminology. British Journal of Clinical Pharmacology. 2017;83(12):2615–25. DOI: 10.1111/bcp.13394

4. Mishinova S.A., Zhuravkov A.A., Zhuravko V.K. Use of unlicensed drugs and off-label drug use: focus on COVID-19. Good Clinical Practice. 2020;S4:120–9. DOI: 10.37489/2588-0519-2020-S4-120-129

5. Gabay P.G., Bagmet N.A. Off -label use of pharmaceutical drugs: liability of medical officer and medical institution. Russian Detective. 2017;17:19–24.

6. Martsevich S.Yu., Navasardjan A.R., Komkova N.A. Off-label prescribing. Possible causes, types and consequences. Legal regulation in the Russian Federation. Rational Pharmacotherapy in Cardiology. 2017;13(5):667–74. DOI: 10.20996/1819-6446-2017-13-5-667-674

7. Volskaya E.A. Off-label use - limitations and opportunities. Remedium. 2008;8:6–9.

8. Volskaya E.A. Narrow limits of freedom: off label use of medicinal products. Remedium. 2017;7–8:6–10. DOI: 10.21518/1561-5936-2017-7-8-6-10

9. Dooms M. Declaration on Good Off-Label Use Practice. Av. at: http://www.braincouncil.eu/golup/wp-content/uploads/2015/05/GOLUP-declaration.pdf.

10. Mustafina-Bredikhina D.M. Off-label prescription drugs use: international practice and perspectives on Russia. Neonatology: news, options, training. 2015;1(7):77–9.

11. Zhuchkov M.V., Zakharova S.S., Shilin R.R., Zhuchkova U.V. Legal and medical aspects of off-label use of drugs in dermatology. Dermatology. Supplement to the journal Consilium Medicum. 2017;4:14–6.

12. Weda M, Hoebert J, Vervloet M, Moltó Puigmarti C, Damen N, Marchange S et al. Study on off-label use of medicinal products in the European Union. 2017. Av. at: https://ec.europa.eu/health/sites/health/files/files/documents/2017_02_28_final_study_report_on_off-label_use_.pdf.

13. Saullo F, Saullo E, Caloiero M, Menniti M, Carbone C, Chimirri S et al. A questionnaire-based study in Calabria on the knowledge of off-label drugs in pediatrics. Journal of Pharmacology and Pharmacotherapeutics. 2013;4(5):51–4. DOI: 10.4103/0976-500X.120960

14. Kuznetsova E.Yu., Ovchinnikova P.P., Semyoncheva A.S. The problem of using drugs off-label in Russia. International scientific research journal. 2020;9–1(99):133–8. DOI: 10.23670/IRJ.2020.99.9.022

15. Ministry of Health of Russian Federation. Temporary methodical recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-2019). Version 7 (03.06.2020). Moscow. Av. at: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/584/original/03062020_%D0%9CR_COVID-19_v7.pdf. 2020.

16. Knopf H, Wolf I-K, Sarganas G, Zhuang W, Rascher W, Neubert A. Off-label medicine use in children and adolescents: results of a population-based study in Germany. BMC Public Health. 2013;13(1):631. DOI: 10.1186/1471-2458-13-631

17. Gratsyanskaya A.N., Bolotov A.A., Kostyleva M.N., Postnikov S.S. The use of drugs off label in pediatric practice. Experience of a multidisciplinary pediatric hospital. Deputy chief physician. 2012;8(75):46–53.

18. Titova A.R., Asetskaya I.L., Polivanov V.A., Zyryanov S.K. The Russian study of off-label drug use in pediatric practice: 2015 vs 2012. Good Clinical Practice. 2016;4:54–62.

19. Order of Roszdravnadzor of 15.02.2017 No. 1071 (ed. of 16.07.2020) ‘On Approval of the Procedure for Pharmacovigilance’ (Registered with the Ministry of Justice of the Russian Federation 20.03.2017 № 46039). Av. at: http://www.consultant.ru/document/cons_doc_LAW_214216/. 2017.

20. Titova A.R., Asetskaya I.L., Zyryanov S.K., Polivanov V.A. Off-Label Drug Use in Pediatric Practice: Unsolved Problems. Pediatric pharmacology. 2015;12(3):304–8. DOI: 10.15690/pf.v12i3.1355